December 2, 2019 / 5:40 PM / 13 days ago

BRIEF-Breckenridge Announces Final Approval Of Its ANDA For Rivastigmine Transdermal System (Generic For Exelon Patch)

Dec 2 (Reuters) - Breckenridge Pharmaceutical Inc:

* BRECKENRIDGE PHARMACEUTICAL - U.S. FDA GRANTED FINAL APPROVAL FOR ITS ANDA FOR RIVASTIGMINE TRANSDERMAL SYSTEM (GENERIC FOR EXELON PATCH BY NOVARTIS) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below